Went public 01/31/01
Filing Range:4.0 million shares @ $14 to $16
Shares Outstanding: 18.6 million shares
Underwriters: Merrill Lynch & Co. Inc./CIBC World Markets/ Thomas Weisel Partners LLC
Company Counsel: Testa Hurwitz & Thibeault
Manager Counsel: Shearman & Sterling
Auditor: Arthur Andersen LLP
Develops stool-based early detection test for colorectal cancer. The company has developed proprietary technologies in applied genomics that aids in the early detection of colorectal cancer and several other types of common cancers.
Highland Capital Partners
Greylock Management Corp.
Boston University Community Technology Fund
CB Health Ventures LLC
Robertson Stephens Inc.
HLM Management Co.
PaineWebber Group Inc./McKinley Allsop
Vulcan Ventures Inc.
Galleon Management Inc.
Mayo Medical Ventures
Gilde Venture Fund
Number ofRound Amt.
Round # Round Date Stage Investors ($ thousands)
1 02/01/1995 3 Early Stage 200.0
2 02/01/1996 1 Early Stage 99.0
3 04/01/1996 3 Early Stage 800.1
4 02/01/1997 5 Early Stage 3935.0
5 03/17/1998 10 Expansion 10575.2
6 04/03/2000 19 Later Stage 31895.0
(Data in $ millions)
Total Revenues: $0.0
Net Income (5.0)